首页> 外文期刊>Journal of Clinical Oncology >Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for
【24h】

Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for

机译:非霍奇金淋巴瘤的同种异体造血干细胞移植:与同种异体和自体移植的比较-国际骨髓移植登记处淋巴瘤工作委员会和欧洲肝移植小组

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To compare results of syngeneic, allogeneic, and autologous hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma (NHL). PATIENTS AND METHODS: The databases of the International Bone Marrow Transplant Registry (IBMTR) and the European Group for Blood and Marrow Transplantation were used to identify 89 NHL patients who received syngeneic transplants. These patients were compared with NHL patients identified from the IBMTR and the Autologous Blood and Marrow Transplant Registry who received allogeneic (T-cell depleted and T-cell replete) and autologous (purged and unpurged) transplants. RESULTS: No significant differences in relapse rates were observed when results of allogeneic transplantation were compared with syngeneic transplantation for any histology. T-cell depletion of allografts was not associated with a higher relapse risk, but was associated with improved overall survival for patients with low-grade and intermediate-grade histology. Patients who received unpurged autografts for low-grade NHL had a five-fold (P =.008) greater risk of relapse than recipients of syngeneic transplants, and recipients of unpurged autografts had a two-fold (P =.0009) greater relapse risk than patients who received purged autografts. Among low-grade NHL patients, the use of purging was associated with significantly better disease-free survival (P =.003) and overall survival (P =.04) when compared with patients who received unpurged autografts. CONCLUSION: These analyses failed to find evidence of a graft-versus-lymphoma effect, but do provide indirect evidence to support the hypothesis that tumor contamination may contribute to lymphoma relapse, and that purging may be beneficial for patients undergoing autologous hematopoietic stem-cell transplantation for low-grade NHL.
机译:目的:比较同种异体,异体和自体造血干细胞移植治疗非霍奇金淋巴瘤(NHL)的结果。病人和方法:国际骨髓移植登记处(IBMTR)和欧洲血液和骨髓移植小组的数据库用于鉴定接受同种移植的89位NHL患者。将这些患者与从IBMTR和自体血液和骨髓移植登记处确定的,接受异体(T细胞贫乏和T细胞充足)和自体(清除和未清除)移植的NHL患者进行比较。结果:将同种异体移植的结果与同基因移植的任何组织学进行比较时,观察到复发率均无显着差异。同种异体移植物的T细胞耗竭与较高的复发风险无关,但与低度和中度组织学患者的总生存期改善有关。接受低纯度NHL未清除自体移植的患者复发风险比同基因移植接受者高五倍(P = .008),未清除自体移植的患者复发风险高两倍(P = .0009)比接受清除自体移植的患者要多。在低级NHL患者中,与接受未清除自体移植的患者相比,使用清除与无病生存期(P = .003)和总体生存期(P = .04)显着相关。结论:这些分析未能找到移植物抗淋巴瘤作用的证据,但确实提供了间接证据来支持以下假设:肿瘤污染可能导致淋巴瘤复发,并且清除可能对自体造血干细胞移植患者有益适用于低级NHL。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号